Cite
HARVARD Citation
Menzies, A. et al. (2015). Clinicopathologic features associated with efficacy and long‐term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer. 121 (21), pp. 3826-3835. [Online].